We read with great interest the paper by Yun et al. 1) in a recent issue of the Korean Circulation Journal. In their work, the authors highlight that ticagrelor treatment showed less temporal variability of platelet reactivity over time in acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention (PCI) compared to clopidogrel treatment, with a reduced frequency of high-platelet reactivity. However, their work also demonstrated that patients in the ticagrelor group showed a significantly higher incidence of low-platelet reactivity, associated with an increased risk of bleeding, in comparison to the clopidogrel group, at every time point.
https://e-kcj.org
To the Editor:
We read with great interest the paper by Yun et al. 1) in a recent issue of the Korean Circulation Journal. In their work, the authors highlight that ticagrelor treatment showed less temporal variability of platelet reactivity over time in acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention (PCI) compared to clopidogrel treatment, with a reduced frequency of high-platelet reactivity. However, their work also demonstrated that patients in the ticagrelor group showed a significantly higher incidence of low-platelet reactivity, associated with an increased risk of bleeding, in comparison to the clopidogrel group, at every time point.
In patients with acute myocardial infarction (AMI) who undergo PCI, the use of potent P2Y 12 inhibitors, including ticagrelor and prasugrel, is recommended in the current guidelines. 2) Interestingly, the first head-to-head randomized trial of ticagrelor and prasugrel in ACS patients recently reported, demonstrating a benefit of prasugrel in reducing ischemic events without increasing bleeding risk. 3) However, it is important to acknowledge that standard dose ticagrelor (90 mg twice a day) and prasugrel (10 mg/day) have not demonstrated a reduction in the incidence of ischemic events but result in a significant increase in bleeding complications in Korean patients with AMI undergoing PCI when compared with clopidogrel (75 mg/day). 4) This finding could be explained by the vulnerability of bleeding in East Asian patients, which is referred to as "East Asian Paradox". 5) From January 2017 to August 2019, we collected single-center data on platelet reactivity for potent P2Y 12 inhibitors measured by the VerifyNow P2Y 12 (Accumentrics, Inc., San Diego, CA, USA) assay in patients with AMI who underwent PCI with stent implantation. As shown in Figure 1 , the standard-dose potent P2Y 12 inhibitor groups had significantly lower platelet reactivity, expressed as P2Y 12 reaction unit (PRU), compared with that of the 5 mg prasugrel group. Moreover, the 5 mg prasugrel group had the highest proportion of matching the Asian therapeutic window (85<PRU≤275), followed by the 10 mg prasugrel and ticagrelor groups (53.7% vs. 32.0% vs. 14.3%, respectively, p<0.001).
